These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
563 related articles for article (PubMed ID: 33123895)
1. 4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition. Zhao XY; Zhang RR; Ye Q; Qiu F; Xu HY; Wei FG; Zhang H Curr Med Sci; 2020 Oct; 40(5):810-816. PubMed ID: 33123895 [TBL] [Abstract][Full Text] [Related]
2. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. Chen M; Shen C; Chen Y; Chen Z; Zhou K; Chen Y; Li W; Zeng C; Qing Y; Wu D; Xu C; Tang T; Che Y; Qin X; Xu Z; Wang K; Leung K; Sau L; Deng X; Hu J; Wu Y; Chen J Cell Rep Med; 2024 Jul; 5(7):101645. PubMed ID: 39019012 [TBL] [Abstract][Full Text] [Related]
3. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594 [TBL] [Abstract][Full Text] [Related]
5. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500 [TBL] [Abstract][Full Text] [Related]
6. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML. Wu S; Liu F; Gai Y; Carter J; Edwards H; Hüttemann M; Wang G; Li C; Taub JW; Wang Y; Ge Y Leuk Res; 2024 Sep; 144():107547. PubMed ID: 38968731 [TBL] [Abstract][Full Text] [Related]
7. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841 [TBL] [Abstract][Full Text] [Related]
8. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744 [TBL] [Abstract][Full Text] [Related]
9. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives. Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823 [TBL] [Abstract][Full Text] [Related]
10. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia. Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312 [TBL] [Abstract][Full Text] [Related]
11. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360 [TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388 [TBL] [Abstract][Full Text] [Related]
13. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of Kondo T; Onozawa M; Fujisawa S; Harada S; Ogasawara R; Izumiyama K; Saito M; Morioka M; Mori A; Teshima T Hematology; 2021 Dec; 26(1):256-260. PubMed ID: 33631087 [No Abstract] [Full Text] [Related]
14. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622 [TBL] [Abstract][Full Text] [Related]
15. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480 [TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014 [TBL] [Abstract][Full Text] [Related]